Company intelligence / Profile preview

Avexxin

Lund, Sweden

Ownership: Private
Development stage: Other

Overview

AVX420 has demonstrated promising preclinical results in multiple cancer models, including triple-negative breast cancer and acute lymphoblastic leukemia, showing selective cell death induction at nanomolar concentrations in leukemia cells while sparing healthy immune cells.[4] Clinical proof-of-concept has been achieved in psoriasis and actinic keratosis with topical AVX001 formulation.[4]

Therapeutic areas: OncologyImmunologyDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

SINTEF

Beyond the preview

Go deeper on Avexxin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avexxin.

Explore the full profile